Home/Pipeline/KRAS AK™PCR Mutation Screen Kit

KRAS AK™PCR Mutation Screen Kit

Colorectal Cancer

CommercialActive

Key Facts

Indication

Colorectal Cancer

Phase

Commercial

Status

Active

Company

Akcell Biotech

About Akcell Biotech

Founded in 2018 and headquartered in North Miami, Florida, Akcell Biotech is a private, early-revenue stage company operating in the molecular diagnostics space. Its core business involves the sale of proprietary 'AK™PCR' mutation screen kits for key genetic targets like JAK2, BRAF, BRCA1, and KRAS, used in diagnosing various cancers and genetic conditions. The company also lists genomic services, including CRISPR editing and sequencing, suggesting a broader technology services platform alongside its product portfolio.

View full company profile

Therapeutic Areas

Oncology Immunology Hematology Genetic Disorders

Other Colorectal Cancer Drugs

Drug	Company	Phase	Status
CY-101 + Pembrolizumab	Cytovation	Phase 1/2	Initiate 1H-26
M9140	Merck KGaA	Phase 1/2	Active
Repositioned/Rerouted API	Reponex	Not Specified	Active
Leronlimab	CytoDyn	Phase 2	Phase in progress
EGFR inhibitor	Acellera	Pre-clinical	Hit Identification
Cannabics® RCC-33	CNBX Pharmaceuticals	Preclinical	Preparation of Pre-IND Meeting Package
VCR-036	Vicero Bio	Preclinical	Active
CBI-1214	Cartography Biosciences	Phase 1	Active
QL335	QLSF Biotherapeutics	Phase 1	Active
Colorectal Cancer Detection Partnership	Daisy Genomics	Research/Assay Development	Active
High Internalization ADC	Lytica Therapeutics	Preclinical	Active
Undisclosed Colorectal Program(s)	Tavanta Therapeutics	Phase 2	Active